You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 5, May 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lidocaine Plasma Concentrations Following Administration of Intraoral Lidocaine Solution

David J. Greenblatt, MD; David M. Benjamin, PhD; Christopher R. Willis; Jerold S. Harmatz; Miguel A. Zinny, MD

Arch Otolaryngol. 1985;111(5):298-300.


Abstract

• Seventeen healthy male volunteers received 15 mL of 2% solution (300 mg) of lidocaine hydrochloride every three hours for eight consecutive doses. Modes of administration were as follows: (A) each dose washed throughout the oral cavity, then spit out without swallowing; (B) each dose washed, then swallowed; and (C) each dose swallowed directly. Plasma levels of lidocaine and its two metabolites (monoethylglycinexylidide [MEGX] and glycinexylidide [GX]) were measured during and after the period of dosage. In trial A, levels of all three compounds were very low, in no case exceeding 0.3 µg/mL. During trial C, the mean peak levels of lidocaine and MEGX, respectively, were 0.5 and 0.6 µg/mL after the first dose, and 0.8 and 1.3 µg/mL after the eighth dose. Both compounds were essentially undetectable by 12 hours after the last dose. Levels in trial B were very similar to those in trial C. Thus, recommended topical oral cavity use of 2% lidocaine leads to negligible systemic levels of lidocaine and metabolites. Even when doses are swallowed, systemic levels do not approach a toxic range.

(Arch Otolaryngol 1985;111:298-300)



Author Affiliations

From the Division of Clinical Pharmacology, Tufts-New England Medical Center, Boston (Dr Greenblatt and Messrs Willis and Harmatz); the Medical Department, Astra Pharmaceuticals, Worcester, Mass (Dr Benjamin); and Medical and Technical Research Associates, Inc, Needham, Mass, and Boston (Dr Zinny).


Footnotes

Accepted for publication Nov 6, 1984.

Read in part before the 13th annual meeting of the American College of Clinical Pharmacology, Philadelphia, Oct 18, 1984.

Reprint requests to Division of Clinical Pharmacology, Box 1007, Tufts-New England Medical Center, 171 Harrison Ave, Boston, MA 02111 (Dr Greenblatt).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.